Advancing the way brain injuries are detected and managed

Non-invasive, continuous monitoring of brain blood supply for sedated and unconscious patients in intensive care, perioperative and neuro-interventional settings — because the brain can’t wait.

The Problem

6,000,000+_p.a.

Patients worldwide undergo high-risk cardiac, vascular and neurocritical-care procedures with elevated risk of cerebral hypoperfusion and secondary neurological injury.

>10% Bad Outcomes

10% of these patients die, suffer severe or permanent disability, or require longer hospital stays.

The Solution

Wavewise is a decision-support tool, not just a monitor. Every Wavewise alert generates a specific clinical action — vasopressor adjustment, imaging escalation, stroke activation, neurosurgical consult — not a passive observation.

Continuous SurveillanceReal-time, 24/7 multi-channel monitoring throughout surgery and ICU — not intermittent, operator-led snapshots.

Comprehensive Brain CoverageBilateral, multi-territory perfusion data in one device — competitors monitor one artery only.

Early DetectionFlags physiological changes that can indicate stroke, vasospasm, raised ICP or haemorrhage within seconds — not a diagnosis, but a trigger for the appropriate escalation pathway, before clinical signs appear.

Works in Every PatientNo acoustic-window limitations. TCD fails in 10–15% of patients overall due to temporal bone density — disproportionately in populations of colour, worst of all in elderly women of colour.

No Disruption to WorkflowFits directly into existing clinical workflow with no new operator or process — key to clinician adoption.

Reimbursement Pathway ConfirmedA payment pathway has been confirmed with a US DRG, supporting reimbursement from day one.

Market Opportunity

USD$6B+_p.a.

Global market, growing 6–8% CAGR

1M+_p.a.

At-risk procedures in the USA — our initial beachhead

USD$100M

Revenue opportunity by 2033 (~70+ hospitals, ~31,000 patients monitored)

Path to Market

Apr 2026 — FDA Q-Sub agreed likely predicate.
2027 — Bench testing complete; FDA Breakthrough Designation targeted.
Jul 2028 — Target FDA 510(k) clearance and CE mark → access to 75% of the global market.
Cleveland Clinic model — cardiac ICU alone: $8.6M net annual saving to the hospital, 51% net ROI over standard of care.

Building an Unassailable IP Moat

Legal: Patent family 1 (continuous, non-invasive extracranial circulation) · provisional patent #2 (sensor fusion)
Regulatory: FDA Breakthrough Designation pathway · CE Mark · QMS
Technology: Proprietary computational flow-dynamics and AI prediction models, trained on a large cerebrovascular dataset
Commercial lock-in: Procedural consumable model embedded in high-risk surgery and ICU workflows

Team & Board

Dr Mary-Beth BrinsonCEO / Early Commercialisation

Andrew MaxwellNon-Executive Director / Chair

Dr Elliot TeoNeuroscientist

Hon Jaala PulfordNon-Executive Director

Kevin FischerCFO

Dr Barry DixonFounder, Non-Executive Director

Hedi ZivDoppler Design Engineer

Investment Offer

$3.5MRaise (up to $5M)*

$5MPre-money

SASPSenior Preference Shares

$1.5MFirst close threshold

Dr Mary-Beth Brinson CEO, Wavewise Analytics
mbbrinson@wavewise.com
+61 484 300 299

*The Board would consider applications up to $5M to accelerate the path to FDA clearance. A first close will occur once applications exceed $1.5M; the raise will continue up to the stated maximum. This document is confidential and is provided for discussion purposes only to prospective investors — it is not a disclosure document or an offer of securities, and does not constitute financial product advice. Projections are management assumptions only and are not guarantees of future performance. © Wavewise Analytics Pty Ltd (ACN 628 808 088).